NEW YORK (AFX) - U.S. stocks traded mixed Friday, with the technology sector in focus as Google rallied on its inclusion in the S&P 500, and Lucent Technologies surged on merger talks with France's Alcatel.
The Dow Jones Industrial Average was down 6.5 points to 11,263.
The Nasdaq Composite Index gained nearly 4 points to 2,303 while the S&P 500 Index dipped 1 point to 1,300.27.
'There was good news from Google, some bad news out of biotech with Cephalon but there's not much else to drive stocks. We're looking ahead next week to the FOMC meeting which will probably mean a quiet day,' said John Hughes, managing director of Epiphany Equity Research.
The Federal Open Market Committee, the Fed's interest-rate setting body, meets next Tuesday. The FOMC is widely expected to raise its Fed funds rate by a quarter percentage point to 4.75%.
The latest durable goods report offered a mixed picture on the economy.
Total durable goods orders rose 2.6% in February, spurred by demand for civilian aircraft and defense goods, the Commerce Department reported. Economists polled by MarketWatch had been expecting orders to rise 1.5%.
Excluding transportation, however, fell 1.3% in February, the first decline in the last four months.
After the data, the U.S. dollar remained mixed. The euro was up 0.1% at $1.1977. Against the Japanese yen, the greenback climbed 0.5% to 118.42.
Gold futures rose in early trading after logging a three-session loss on Thursday. The benchmark April contract was last up $4 at $554.80 an ounce.
On the bond market, long-term Treasury prices edged higher, sending yields lower. The benchmark 10-year note was up 2/32 at 98 6/32, with its yield at 4.727%.
Also on the data front, a report on new home sales in February is slated for release at 10 a.m. Eastern time. Economists polled by MarketWatch are forecasting a dip in sales to 1.21 million from 1.23 million in the prior month. Stronger-than-expected existing home sales data on Thursday, however, may have some investors thinking Friday's housing data may surprise on the upside.
Crude-oil futures edged higher, finding support in data showing the first drawdown in U.S. supplies in six weeks and continued concerns about supplies from Nigeria, Iran and Iraq.
Crude for May delivery was last up 24 cents at $64.15 a barrel.
Google added to the S&P 500
Shares in Google Inc. surged 7.5% to $367.65 after Standard & Poor's said it would add the leader in Internet search to its benchmark S&P 500 Index at the close of trading on March 31.
The decision instantly puts Google - less than two years after going public - on the shopping list of hundreds of mutual fund managers who run portfolios that track the components of the S&P 500.
Lucent, Alcatel talk
Lucent Technologies Inc. and Alcatel SA are in advanced discussions about a $33 billion merger that could signal the start of a new wave of consolidation in the telecommunications-equipment industry.
The companies, which broke off previous tie-up talks in 2001, said Thursday night they're discussing a 'merger of equals' that would be priced at market -- meaning no stock-price premium. A tie-up would give Alcatel, Europe's second-largest telecom-gear maker, better access to U.S. telecom operators.
Lucent shares shot up 10.6% to $3.12 while U.S.-listed shares of Alcatel climbed 3.4% to $15.97.
Rival U.S. gear maker, Nortel Networks Corp. was up 4.6% at $2.94 in early trading.
Other stock standouts
Also on the merger and acquisition front, Germany's Bayer AG said it would top the offer from Merck KgaA for drug company Schering AG with a $19.5 billion white-knight bid for the German drug maker.
U.S.-listed shares of Bayer rose 63 cents to $42.32. Schering shares climbed 3.7% to $103.29. Merck, which is not connected to the U.S. company of the same name, does not trade in the U.S. but its shares were down 2% in Europe.
Shares in Palm Inc. rose 5.5% to $21.24 after the company posted forecast-beating quarterly results on the back of strong demand for its Treo handheld communications devices. Palm also offered a profit outlook ahead of current Wall Street estimates.
Cephalon shares tumbled 14% to $63.02 after a U.S. Food and Drug Administration panel rejected Sparlon, its attention deficit disorder drug over safety concerns. Cephalon cut its 2006 sales forecast as result of the FDA decision.
J.P. Morgan downgraded the drug company to neutral from overweight. 'The product continues to look approvable in our view, but is likely to be significantly delayed since the panel recommended FDA ask for more data about its safety.' On Thursday, Cephalon shares were halted ahead of the FDA panel recommendation. This story was supplied by MarketWatch. For further information see www.marketwatch.com.
© 2006 AFX News